Kezar Life Sciences, Inc. (KZR) Earnings History
Net Loss10 years of earnings data (2016–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Kezar Life Sciences, Inc. (KZR) Earnings Overview
As of July 8, 2026, Kezar Life Sciences, Inc. (KZR) reported trailing twelve-month net income of -$45M, reflecting -566.1% year-over-year growth. The company earned $-6.16 per diluted share over the past four quarters.
Looking at the long-term picture, KZR's historical earnings data spans multiple years. The company achieved its highest annual net income of -$9M in fiscal 2017.
Kezar Life Sciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$506M net income), ARQT (-$2M net income, -4.3% margin), PRAX (-$327M net income), KZR has comparable earnings metrics. Compare KZR vs IMVT →
KZR Earnings vs Peers
Earnings metrics vs comparable public companies
KZR Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$56M | +33.1% | -$52M | $-7.66 | - | - |
| 2024 | -$84M | +17.8% | -$91M | $-1.15 | - | - |
| 2023 | -$102M | -49.3% | -$111M | $-1.40 | -1455.3% | -1591.8% |
| 2022 | -$68M | -24.9% | -$71M | $-1.01 | - | - |
| 2021 | -$55M | -30.9% | -$55M | $-1.04 | - | - |
| 2020 | -$42M | -19.0% | -$43M | $-0.95 | - | - |
| 2019 | -$35M | -51.5% | -$38M | $-1.65 | - | - |
| 2018 | -$23M | -172.0% | -$25M | $-1.22 | - | - |
| 2017 | -$9M | +5.3% | -$9M | $-0.65 | - | - |
| 2016 | -$9M | - | -$9M | $-0.69 | - | - |
Download Data
Export KZR earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
KZR — Frequently Asked Questions
Quick answers to the most common questions about buying KZR stock.
What is KZR earnings per share (EPS)?
KZR trailing twelve-month (TTM) diluted EPS is $-6.16, reflecting -566.1% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2016 to 2025 is available in the table on this page.
What is Kezar Life Sciences, Inc.'s net income?
Kezar Life Sciences, Inc. (KZR) trailing twelve-month net income is $-45M as of 2025. Earnings declined -566.1% year-over-year.
Is KZR profitable?
KZR is not currently profitable on a TTM basis, reporting a net loss of $-45M. Net margin is N/A. Investors should monitor for a return to profitability.
What is KZR's earnings growth rate?
KZR compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2016 to 2025.
What are KZR's profit margins?
Kezar Life Sciences, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -59.9%.
Is KZR growing earnings?
KZR earnings are declining — EPS fell -566.1% year-over-year. TTM net income dropped to $-45M. This contrasts with the 5-year CAGR of N/A.
What was KZR's best earnings year?
Kezar Life Sciences, Inc.'s highest annual net income on record is $-9M, achieved in fiscal year 2017. Earnings history on this page spans 2016 to 2025 and includes all annual and quarterly figures.
What were KZR's earnings last quarter?
KZR's most recent reported quarter was Q1 2026. Net income was $-6M with diluted EPS of $-0.78. For a full breakdown of all quarters, see the quarterly earnings table on this page.